• Explore /
  • Poster
  • / A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

Abstract Poster

Authors

Miguel Villalona-Calero

Miguel Angel Villalona-Calero

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA

Miguel Angel Villalona-Calero , Stephen J. Forman , Joycelynne Palmer , Timothy W. Synold , Lei Tian , Ting Lu , Colt A. Egelston , Erminia Massarelli , Ravi Salgia , Teresa Kim , W Hans Meisen , Jianying Zhang , Thomas Waddington , F. Edward Boas , Lihua Elizabeth Budde , Omer Butt , Remus N. Vezan , Michael A. Caligiuri , Jianhua Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT05334329

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS2665)

DOI

10.1200/JCO.2023.41.16_suppl.TPS2665

Abstract #

TPS2665

Poster Bd #

506a

Abstract Disclosures

Similar Posters

First Author: Diane Damotte

First Author: Marie Cumberbatch

First Author: Felix Blanc-Durand

Poster

2021 Genitourinary Cancers Symposium

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

First Author: Vivek Narayan